found glp-1 New Pill Foundayo (Orforglipron) Gets FDA Approval for Obesity What are GLP-1s? | Mendinground

For homogeneous binding, cells were incubated in binding buffer with a constant concentration of 125 I-GIP 1-42 (30 pM, PerkinElmer) and increasing concentrations of unlabeled peptide agonists (3.57 pM to 5 M) at RT for 3 h

The GIP component adds: Enhanced Insulin Response: Even stronger blood sugar control than GLP-1 alone Better insulin secretion timing Improved insulin sensitivity in tissues Fat Metabolism Effects: GIP receptors exist in fat tissue May influence how body stores and uses fat Potentially increases fat burning Synergistic Appetite Suppression: GIP and GLP-1 together produce greater appetite reduction More potent satiety signals Stronger overall effect This explains why tirzepatide produces 5-7% more weight loss than semaglutidethe dual action is more powerful than GLP-1 alone

When administered, these medications work through several mechanisms: Slowing gastric emptying - Food remains in the stomach longer, which can contribute to feelings of fullness Reducing appetite signaling - The medications act on brain regions involved in hunger and satiety Improving insulin secretion - In response to food intake, insulin release becomes more efficient, which is why these medications were originally developed for diabetes Decreasing glucagon secretion - This hormone raises blood sugar, so reducing it helps with glucose control The two primary GLP-1 receptor agonists used for weight loss are: Semaglutide - FDA-approved for weight management under the brand name Wegovy (also sold as Ozempic for diabetes and Rybelsus as an oral diabetes medication)

February 3, 2026: Man Sues Ozempic, Claims the Injectable Semaglutide Caused Him to Lose Sight A man from Ohio has filed a legal claim against Ozempics manufacturer, Novo Nordisk, alleging that he developed NAION after taking Ozempic as prescribed